Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of long-chain non-coding RNA RP11-224O19.2 inhibitor

A long-chain non-coding, inhibitor technology, applied in the field of molecular biology, can solve the problem that the function of RP11-224O19.2 has not been reported yet.

Inactive Publication Date: 2017-09-29
SOUTHWEST JIAOTONG UNIV
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The function of RP11-224O19.2 has not been reported yet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of long-chain non-coding RNA RP11-224O19.2 inhibitor
  • Application of long-chain non-coding RNA RP11-224O19.2 inhibitor
  • Application of long-chain non-coding RNA RP11-224O19.2 inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Design and screening of siRNA targeting RP11-224O19.2

[0034] 1. Design and synthesis of siRNA targeting RP11-224O19.2

[0035] The siRNA targeting RP11-224O19.2 and its corresponding control siRNA (negative control siRNA) were designed by us. The sequence is shown in Table 2, and then we commissioned a company to synthesize the double-stranded siRNA sequence.

[0036] 2. Experimental grouping and cell transfection

[0037] Experimental grouping: cells were divided into 3 groups according to different treatment conditions. The experimental group (RP11-224O19.2-siRNA group) was HepG2 cells transfected with siRNA with high interference efficiency; the negative control group (Negative control siRNA group) was HepG2 cells transfected with negative control siRNA; blank group (Control group) is HepG2 cells without any treatment.

[0038] The routine culture operation of HepG2 cells is as follows:

[0039] 1) Cell recovery: Liver cancer HepG2 cells were preserved...

Embodiment 2

[0074] Example 2 siRNA targeting RP11-224O19.2 for the treatment of liver cancer

[0075] In this experiment, the expression of RP11-224O9.2 was inhibited by transfecting siRNA to verify its effect on liver cancer.

[0076] 1. Effects of inhibiting RP11-224O19.2 on the proliferation, colony formation and apoptosis of liver cancer cells

[0077] 1. CCK8 assay to detect the proliferation of HepG2 cells

[0078] The experimental steps are as follows:

[0079] 1) Plate the HepG2 cells of the transfected experimental group and the negative control group and the HepG2 cells of the untreated blank group in a 96-well plate at a plating density of 3000 cells / well, and set up a 6-well experimental group for each 96-well plate , 6-well negative control group and 6-well blank group, another 6 wells were set up for zero adjustment only with medium, and a total of 5 96-well plates were inoculated. After the plating was completed, the 96-well plates were placed in the incubator for cultiva...

Embodiment 3

[0151] Example 3 The relationship between the expression level of RP11-224O19.2 and liver cancer

[0152] Analysis of the expression of RP11-224O19.2 in liver cancer:

[0153] The data analysis method is as follows: All experimental data were analyzed using SPSS 19.0 software (IBM SPSS), and P<0.05 between groups calculated by student's t-test was used as the statistical difference threshold, and the drawing was completed with Origin 8.0 and GraphPadPrism 5 software. According to the fold change of the expression level of RP11-224O19.2, 50 clinical cases of liver cancer were classified. The correlation analysis between the fold change of the expression level of RP11-224O19.2 and the clinicopathological parameters was completed by SPSS19.0 software. The Mann-Whitney U test method in the non-parametric test was used for the analysis among three samples, and the Kruskal-Wallis test method in the non-parametric test was used for the analysis among the three samples, and P<0.05 was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of a long-chain non-coding RNA RP11-224O19.2 inhibitor in preparation of a drug for treating tumors. The invention further provides a drug for treating the tumors, and a kit for liver cancer screening and / or liver cancer prognosis diagnosis. The application shows that the RNA RP11-224O19.2 inhibitor has a significant treatment effect on the tumors. In addition, the expression level of RNA RP11-224O19.2 is detected, and the long-chain non-coding RNA RP11-224O19.2 inhibitor can be applied to auxiliary diagnosis and prognosis judgment of a clinical liver cancer and is good in application prospect.

Description

technical field [0001] The invention belongs to the field of molecular biology, and specifically relates to the use of a long-chain non-coding RNA RP11-224O19.2 inhibitor in the preparation of drugs for treating tumors. Background technique [0002] Liver cancer is a highly malignant tumor with high metastasis rate, high mortality rate and poor prognosis, which poses a serious threat to human health and life. The etiology of liver cancer is still not completely clear. It is generally believed that the causes include chronic hepatitis B and C virus infection, alcohol abuse, and intake of poisonous food. At present, the main treatments for liver cancer include liver transplantation, surgical resection, radiotherapy, chemotherapy, and targeted therapy. The short-term survival rate of liver cancer patients has increased to some extent, but the overall mortality rate and postoperative recurrence rate remain high. [0003] Long noncoding RNA (Long noncoding RNA, LncRNA) is a type...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/713A61P35/00C12N15/113C12Q1/68
CPCA61K31/713C12N15/1135C12N2310/141C12Q1/6886C12Q2600/158C12Q2600/178
Inventor 郭志云熊莉丽刘文荣
Owner SOUTHWEST JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com